Intervacc AB (IVACC) AI Stock Analysis

• Market Cap: €317.64M
• Dividend Yield: N/A
• Average Volume (3M): 393.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 56.48%
• EPS Growth: 40.18%
• Country: SE
• Employees: 15
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 340,813,200
• 10 Day Avg. Volume: 428,785
• 30 Day Avg. Volume: 393,958
• PEG Ratio: -0.14
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: kr1.00 ▲(7.53%Upside)

Intervacc AB's stock score is primarily impacted by its weak financial performance and unattractive valuation. The lack of profitability and negative cash flows are significant risks, while bearish technical signals further contribute to the cautious outlook.

Intervacc AB Business Overview & Revenue Model

Company Description

Intervacc AB (IVACC) is a Swedish biotechnology company that specializes in the development of novel vaccines for animals. Operating primarily within the veterinary health sector, the company focuses on creating innovative solutions to combat infectious diseases affecting livestock and companion animals. Their core products include Strangvac, a vaccine developed to protect horses against strangles, a highly contagious equine disease.

How the Company Makes Money

Intervacc AB generates revenue primarily through the sale and distribution of its veterinary vaccines. The company's main revenue stream comes from Strangvac, which is marketed and sold to veterinary clinics, horse owners, and equine organizations. Intervacc also engages in strategic partnerships and collaborations with veterinary pharmaceutical companies for the distribution and co-development of vaccines, further contributing to its earnings. Additionally, the company may receive funding and grants for its research and development efforts from governmental or industry sources, supporting its ongoing innovation and product development initiatives.

Intervacc AB Financial Statement Overview

Summary

Intervacc AB faces substantial financial challenges, including consistent net losses and negative cash flows. While the balance sheet is bolstered by strong equity and no debt, the negative profitability and cash flow trends present significant risks.

Income Statement

Intervacc AB's income statement reveals significant challenges. The company experienced a negative gross profit margin and substantial net losses in recent years, indicating difficulties in covering production costs and achieving profitability. Revenue growth has been inconsistent, with a significant decline in recent periods, which poses a risk to future financial stability.

Balance Sheet

The balance sheet of Intervacc AB shows a strong equity base with no debt, indicating low financial leverage and reduced risk of insolvency. However, the decline in total assets over the years suggests a reduction in company resources. The high equity ratio is a positive sign of financial stability, though it is offset by diminishing assets.

Cash Flow

Intervacc AB's cash flow statements highlight ongoing operating cash flow deficits, which could strain liquidity. Despite the negative free cash flow, the absence of financial debt provides some relief. Nonetheless, the company needs to enhance its cash generation capabilities to sustain operations and fund growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.97M	11.79M	8.02M	9.68M	5.24M	4.78M
Gross Profit	-1.54M	-3.53M	-13.81M	3.37M	6.25M	4.64M
EBITDA	-54.32M	-58.75M	-68.98M	-57.73M	-23.15M	-19.39M
Net Income	-71.30M	-75.52M	-102.85M	-64.16M	-29.38M	-25.60M
Balance Sheet
Total Assets	363.31M	187.32M	259.61M	265.04M	329.39M	355.28M
Cash, Cash Equivalents and Short-Term Investments	216.09M	34.40M	88.34M	45.70M	115.71M	164.25M
Total Debt	97.00K	145.00K	181.00K	322.00K	433.00K	383.00K
Total Liabilities	20.75M	24.99M	21.68M	14.88M	21.14M	17.67M
Stockholders Equity	342.56M	162.33M	237.93M	250.16M	308.25M	337.61M
Cash Flow
Free Cash Flow	-49.19M	-53.90M	-47.94M	-75.92M	-48.67M	-31.50M
Operating Cash Flow	-48.58M	-53.20M	-45.83M	-69.79M	-25.46M	-20.08M
Investing Cash Flow	-614.00K	-706.00K	-2.11M	-6.13M	-23.13M	-11.27M
Financing Cash Flow	193.41M	-36.00K	90.58M	5.91M	50.00K	143.06M

Intervacc AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IVACC, the sentiment is Neutral. The current price of 0.93 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.05, and below the 200-day MA of 1.44, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.72 is Neutral, neither overbought nor oversold. The STOCH value of 61.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:IVACC.

Intervacc AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMU	51 Neutral	kr421.36M	―	-18.79%	―	―	21.85%
IMMU	51 Neutral	kr421.36M	―	-18.79%	―	―	21.85%
Sector *	46 Neutral	C$194.90M	-3.46	-23.22%	2.62%	21.17%	-0.58%
XBRANE	44 Neutral	€373.85M	―	-47.73%	―	45.52%	93.35%
XBRANE	44 Neutral	€373.85M	―	-47.73%	―	45.52%	93.35%
IVACC	44 Neutral	€317.64M	―	-24.61%	―	56.48%	40.18%
ONCO	40 Neutral	kr367.60M	―		―	1.72%	32.54%
ONCO	40 Neutral	kr367.60M	―		―	1.72%	32.54%
GUARD	32 Underperform	€348.90M	―	-205.65%	―	―	24.25%
CANTA	31 Underperform	kr323.69M	―	-167.55%	―	―	46.67%